|
Systemic sclerosis
|
UVA
|
-
|
-
|
requires evaluation
|
| |
UVA128–31
|
low-/medium-dose
|
E, C
|
benefit, especially suited for acrosclerosis and partial body exposure
|
| |
PUVA18,32–34
|
medium-dose
|
E, D
|
bath application in childhood discussed
|
|
Localized scleroderma
|
UVA36,37
|
low-dose
|
C
|
benefit, no further evaluation
|
| |
UVA138–45
|
low-/medium-/high-dose
|
D, C
|
no exact recommendation in favor to best dosage, benefit, combination with calcipotriol where appropriate, successful in childhood/adolescence
|
| |
PUVA19,32,34,46–51
|
high-dose
|
E, D
|
questionable efficacy, extreme variance in dosage, combination (cream) with calcipotriol in childhood
|
|
Extragenital lichen sclerosus et atrophicus
|
UVA
|
-
|
-
|
requires evaluation
|
| |
UVA140,56–58
|
low-dose
|
E, D, C
|
effectiveness, disputable in combined morphea/lichen sclerosis et atrophicus
|
| |
PUVA59,60
|
low-dose
|
E
|
benefit, careful cream therapy for genitoanal lesions where appropriate
|
|
Sclerodermoid graft- vs-host disease
|
UVA
|
-
|
-
|
requires evaluation
|
| |
UVA162–64
|
low-/medium-dose
|
E, D
|
partial efficacy, medium-dose possibly more effective than low-dose, combined UV/immunosuppressive therapy
|
| |
PUVA65–71
|
medium-dose
|
E, D, C
|
skeptical effectiveness, potentially adjunct therapy in addition to conventional chemotherapy, more effective in lichenoid than sclerodermoid lesions
|
|
Lupus erythematosus
|
UVA
|
-
|
-
|
requires evaluation
|
| |
UVA173–78
|
low-dose
|
D, C, A
|
benefit in occasional cases, long-term application
|
| |
PUVA
|
-
|
-
|
requires evaluation
|
